News | November 18, 2014

First Patients Enrolled in Gore Thoracoabdominal Aortic Aneurysm Clinical Study

Device offers endovascular system specifically designed to treat aortic aneurysms involving visceral branch vessels

Aortic Aneurysm, stent graft, Gore Excluder

November 18, 2014 — Pierre Galvagni Silveira, M.D., Ph.D., from the Federal University of Santa Catarina in Florianopolis, Brazil, enrolled the first two patients in the Gore Thoracoabdominal Aortic Aneurysm Clinical Study. This initial feasibility study of the Gore Excluder Thoracoabdominal Branch Endoprosthesis will assess the safety of the device implantation procedure in the treatment of abdominal aortic aneurysms encroaching on or involving visceral branch vessels.

Currently, treatment options for patients with abdominal aortic aneurysms involving the visceral segment are limited, with physicians often having to rely on endovascular devices that are not designed for this purpose. The Gore Thoracoabdominal Study seeks to assess the feasibility of Gore Excluder Thoracoabdominal Branch Device. The system of devices is designed to provide physicians with a complete “off-the-shelf” endovascular solution for aortic aneurysms encroaching on or involving the visceral section of the aorta.

Deployed via an intuitive staged delivery system, the device gives endovascular surgeons the ability to reposition the partially deployed graft to aide in selective catheterization of the branches. The Gore Excluder Thoracoabdominal Branch Endoprosthesis includes four pre-cannulated portals for placement of stent-graft branches for the visceral branch vessels, intended to enable a faster, more precise implant.

Gore intends to follow this Phase 1 clinical study in Brazil with an early feasibility study in the United States.

Gore has achieved several other key milestones in its commitment of providing the most complete portfolio of products intended to durably treat the aorta. The Gore Tag Thoracic Branch Endoprosthesis received FDA approval earlier this year for an investigational device exemption (IDE) trial in the treatment of thoracic aortic aneurysms that require coverage of the left subclavian artery (LSA). Gore also recently gained approval to begin another early feasibility study for the GORE TAG Thoracic Branch Endoprosthesis through the FDA’s Innovation Pathway Program to assess the treatment of Zone 0/1 aortic arch aneurysms. In October 2013, the Gore Excluder Iliac Branch Endoprosthesis received CE mark for the treatment of common iliac artery aneurysms and is currently enrolling an IDE study in the U.S.

For more information: www. goremedical.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init